verapamil has been researched along with Ovarian Hyperstimulation Syndrome in 2 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Ovarian Hyperstimulation Syndrome: A complication of OVULATION INDUCTION in infertility treatment. It is graded by the severity of symptoms which include OVARY enlargement, multiple OVARIAN FOLLICLES; OVARIAN CYSTS; ASCITES; and generalized EDEMA. The full-blown syndrome may lead to RENAL FAILURE, respiratory distress, and even DEATH. Increased capillary permeability is caused by the vasoactive substances, such as VASCULAR ENDOTHELIAL GROWTH FACTORS, secreted by the overly-stimulated OVARIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy of pathways inhibition and the combined effect of Everolimus (mTOR inhibitor) and Verapamil (CYP3A inhibitor) in ovarian hyperstimulation syndrome (OHSS) need to be tested." | 7.83 | The combination of Everolimus with Verapamil reduces ovarian weight and vascular permeability on ovarian hyperstimulation syndrome: a preclinical experimental randomized controlled study. ( Dalkalitsis, A; Georgiou, I; Kitsou, C; Kosmas, I; Lazaros, L; Mynbaev, O; Prapas, I; Prapas, N; Tinelli, A; Tzallas, C, 2016) |
| "The efficacy of pathways inhibition and the combined effect of Everolimus (mTOR inhibitor) and Verapamil (CYP3A inhibitor) in ovarian hyperstimulation syndrome (OHSS) need to be tested." | 3.83 | The combination of Everolimus with Verapamil reduces ovarian weight and vascular permeability on ovarian hyperstimulation syndrome: a preclinical experimental randomized controlled study. ( Dalkalitsis, A; Georgiou, I; Kitsou, C; Kosmas, I; Lazaros, L; Mynbaev, O; Prapas, I; Prapas, N; Tinelli, A; Tzallas, C, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kitsou, C | 2 |
| Kosmas, I | 2 |
| Lazaros, L | 2 |
| Hatzi, E | 1 |
| Euaggelou, A | 1 |
| Mynbaev, O | 2 |
| Tournaye, H | 1 |
| Prapas, N | 2 |
| Prapas, I | 2 |
| Zikopoulos, K | 1 |
| Galani, V | 1 |
| Georgiou, I | 2 |
| Tzallas, C | 1 |
| Tinelli, A | 1 |
| Dalkalitsis, A | 1 |
2 other studies available for verapamil and Ovarian Hyperstimulation Syndrome
| Article | Year |
|---|---|
Ovarian hyperstimulation syndrome inhibition by targeting VEGF, COX-2 and calcium pathways: a preclinical randomized study.
Topics: Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Calcium Signaling; Cyclooxygenase 2 Inhibit | 2014 |
The combination of Everolimus with Verapamil reduces ovarian weight and vascular permeability on ovarian hyperstimulation syndrome: a preclinical experimental randomized controlled study.
Topics: Animals; Capillary Permeability; Cytochrome P-450 CYP3A Inhibitors; Disease Models, Animal; Everolim | 2016 |